Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

383
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
383
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

527
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
527
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

423
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
423
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

1.6K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.6K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Immunovirological Characteristics Associated with Cardiovascular Dysautonomia in Long COVID.

Journal of clinical medicine·2026
Same author

Sex-specific cardiometabolic responses during microgravity simulation in European Space Agency VIVALDI dry immersion.

Communications medicine·2026
Same author

The LRRK2 G2385R Exonic Variant: A Potential Genetic Disease Modifier of Multiple System Atrophy?

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Setting up an autonomic unit within the neurological department: a position statement of the European Federation of Autonomic Societies.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same author

Reply to: Deep Learning to Differentiate Parkinsonian Syndromes: From Proof of Concept to Clinical Trust.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

Stridor Is an Independent Risk Factor for Mortality and Disease Progression in Patients with Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2025

Related Experiment Video

Updated: May 1, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

11.3K

A cross-sectional study on drug use in multiple system atrophy.

María Verónica Rey1, Santiago Perez-Lloret, Anne Pavy-Le Traon

  • 1Departments of Clinical Pharmacology and Neurosciences, Faculty of Medicine, University Hospital and University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France, mverorey@yahoo.com.ar.

CNS Drugs
|April 1, 2014
PubMed
Summary

Multiple system atrophy (MSA) and Parkinson disease (PD) patients use multiple medications. MSA patients frequently use laxatives, antidiabetics, and antihypotensives, highlighting a need for better evidence-based treatment evaluations in MSA.

More Related Videos

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
10:19

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

15.6K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K

Related Experiment Videos

Last Updated: May 1, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

11.3K
High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
10:19

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

15.6K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Therapeutics

Background:

  • Drug utilization in multiple system atrophy (MSA) is understudied, despite frequent treatments lacking robust evidence.
  • Understanding medication patterns is crucial for optimizing care in neurodegenerative diseases.

Purpose of the Study:

  • To analyze and compare drug use patterns in patients with multiple system atrophy (MSA) and Parkinson disease (PD).
  • To identify differences in medication prescriptions between MSA and PD cohorts using a French reference center database.

Main Methods:

  • Retrospective analysis of medication data from 147 MSA and 180 age/sex-matched PD patients.
  • Assessment of motor and autonomic symptoms in MSA patients using the Unified MSA Rating Scale (UMSARS) and SCOPA-Autonomic scales.

Main Results:

  • Both MSA and PD patients received an average of five medications.
  • MSA patients showed higher use of laxatives, antidiabetics, antihypotensives, muscarinic antagonists, alpha-adrenergic blockers, and antidepressants compared to PD patients.
  • Levodopa use was lower in cerebellar MSA (MSA-C) than parkinsonian MSA (MSA-P) and PD patients; dopamine agonist use was higher in PD than MSA.

Conclusions:

  • Observed drug use differences between MSA and PD align with symptom profiles, including motor, autonomic, and mood disturbances.
  • Many drugs are used in MSA without strong benefit-risk data, necessitating further evaluation.
  • Increased consumption of certain medications like antidiabetics in MSA warrants further investigation into underlying reasons.